Protara Therapeutics FY Conference Summary Company Overview - **Company**: Protara Therapeutics (NasdaqGM:TARA) - **Lead Program**: TARA-002, a bacterial therapeutic for Non-Muscle Invasive Bladder Cancer (NMIBC) and lymphatic malformations Key Points on TARA-002 and NMIBC - **Mechanism of Action**: TARA-002 is a whole cell bacterial therapeutic engineered to retain antigens while eliminating toxicities associated with traditional treatments. It aims to stimulate a broad immune response without the adverse effects of streptolysin or Streptococcus pyogenes exotoxin [8][10] - **Historical Context**: Originally developed by Chugai Pharmaceutical in the 1970s, TARA-002 (formerly OK-432) has been used in over 65,000 patients in Japan for various cancers, demonstrating significant survival benefits [9][10] - **Current Efficacy Data**: - **BCG-unresponsive Patients**: - 68% complete response (CR) at 6 months, the highest reported in the field [23] - 65% CR at any time [24] - 33% CR at 12 months from a recent update [34] - **BCG-naive Patients**: - 72% CR at any time, 68% CR at 6 months, and 58% CR at 12 months [48] - **Regulatory Pathway**: The FDA has approved a single-arm open-label study for BCG-unresponsive patients, with a focus on CR at 6 months as the primary endpoint [41][57] Competitive Landscape - **Market Positioning**: TARA-002 is positioned as a compelling alternative to existing treatments, with a focus on safety, tolerability, and ease of administration. It is expected to have a significant market share due to its unique mechanism and favorable safety profile [89][92] - **Revenue Potential**: The addressable patient population for TARA-002 is estimated to exceed 20,000 in the frontline plus BCG-exposed settings, which presents a substantial revenue opportunity [41] Lymphatic Malformations Program - **Regulatory Update**: A Type C meeting with the FDA is scheduled, expected to clarify the regulatory path for TARA-002 in treating lymphatic malformations [100] - **Market Opportunity**: The company targets macrocystic and mixed cystic lesions, with an estimated 800 addressable patients annually in the U.S. [110] Choline Program - **Overview**: IV Choline Chloride is aimed at patients on parenteral support, with a significant portion being choline deficient. The FDA has agreed on a pivotal study with a primary endpoint of serum choline elevation [116] Conclusion - Protara Therapeutics is positioned for significant growth with multiple registrational studies underway, focusing on TARA-002 for NMIBC and lymphatic malformations, alongside the choline program. The company emphasizes a strong safety profile, efficacy, and a clear regulatory pathway as key drivers for future success [117][120]

Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, reflecting significant growth due to the $65 million upfront payment from AstraZeneca and other milestone payments [17][18] - R&D expenses for Q4 2025 were approximately $5.5 million, down from $5.9 million in Q4 2024, while total R&D expenses for the year were approximately $22.8 million, compared to $24.8 million in 2024, indicating a decrease primarily due to winding down prior clinical trials [18] - The company reported a net profit of approximately $56.8 million for Q4 2025, or approximately $0.60 per share, compared to a net loss of approximately $6.1 million in Q4 2024 [19] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with COM-701 showing promising results in the MAIA-ovarian trial [5][10] - The partnership with Gilead for GS-0321 includes potential future milestones of up to $758 million, indicating strong collaboration and financial prospects [12] Market Data and Key Metrics Changes - The company extended its cash runway into 2029, supported by a non-dilutive transaction with AstraZeneca, which is crucial for funding ongoing and future clinical trials [4][16] - AstraZeneca's rilvegostomig is involved in a broad late-stage development program with an estimated peak annual revenue potential of over $5 billion, highlighting the market potential of the company's assets [8] Company Strategy and Development Direction - The company aims to continue executing its MAIA-ovarian adaptive trial and expand its clinical development plan across ovarian cancer and other indications [10][14] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity, positioning the company for its next phase of growth [4][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for COM-701 to address significant unmet medical needs in ovarian cancer [10][33] - The company remains committed to leveraging its computational drug target discovery engine to deliver innovative immune oncology assets, supported by a solid financial outlook [14][15] Other Important Information - The company has diversified its leadership team and is focused on advancing its early-stage pipeline, which is managed by a large team [4][14] - The company retains the majority of its royalty interest in rilvegostomig, ensuring that its economic interests remain intact despite the recent monetization deal [6][7] Q&A Session Summary Question: What to expect in the 1Q 2027 update with COM-701? - Management indicated that the current trial is an adaptive design, and data maturation is expected in Q1 2027, with the timeline for registration depending on the totality of the data [23][24] Question: Cadence of potential milestones for rilvegostomig? - The next milestone payment is expected upon BLA acceptance, which will trigger an additional $25 million payment, with a total of $195 million in future milestones from AstraZeneca [27][28] Question: Shift in interim analysis timing for the ovarian trial? - The shift to Q1 2027 was due to slower opening of major academic sites, but all sites are now open, and the trial is on track [32][34] Question: Discussions on expanding the use of COM-902 derived TIGIT? - Management noted that AstraZeneca controls rilvegostomig and is expanding its use, but discussions on COM-902 are separate as the company fully owns it [35] Question: Data expectations for GS-0321? - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety data [36]

Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, reflecting significant growth [17][18] - Net profit for Q4 2025 was approximately $56.8 million or approximately $0.60 per share, compared to a net loss of approximately $6.1 million or approximately $0.07 per share in Q4 2024 [19] - For the full year 2025, net profit was approximately $35.3 million or approximately $0.38 per share, compared to a net loss of approximately $14.2 million or approximately $0.16 per share in 2024 [20] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with significant updates presented at major conferences [5][9] - The partnership with Gilead for GS-0321 includes potential future milestones of up to $758 million and tiered royalties [11] Market Data and Key Metrics Changes - The company extended its cash runway into 2029, assuming no further cash inflows, due to a non-dilutive transaction with AstraZeneca [4][6] - AstraZeneca's rilvegostomig is involved in a broad late-stage development program with an estimated peak annual revenue potential of over $5 billion [7] Company Strategy and Development Direction - The company aims to continue executing its MAIA-ovarian adaptive trial and expand its clinical development plan across ovarian cancer and other indications [9][10] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity for the company's growth [4][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products and the strategic execution of their clinical trials, particularly in the context of the competitive landscape [12][13] - The company remains committed to investing in its early-stage pipeline and leveraging its computational drug target discovery engine [13] Other Important Information - The company has a solid balance sheet with approximately $145.6 million in cash equivalents as of December 31, 2025 [16] - The company is focused on maintaining a favorable safety profile for its products while advancing innovative immune oncology therapies [12] Q&A Session Summary Question: Expectations for the 1Q 2027 update with COM-701 - Management indicated that data maturation is expected in 1Q 2027, with the timeline for registration dependent on the totality of the data [22][23] Question: Cadence of potential milestones for rilvegostomig - The next milestone payment of $25 million is expected upon BLA acceptance, with total remaining milestones up to $195 million [26][27] Question: Shift in interim analysis timing for the ovarian trial - The shift to Q1 2027 was due to slower opening of major academic sites, which are now all operational [30][31] Question: Discussions on expanding the use of COM-902 derived TIGIT - The company clarified that AstraZeneca controls rilvegostomig and is expanding its use, but discussions on COM-902 are separate [33] Question: Data reporting for GS-0321 - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety [34]

Financial Data and Key Metrics Changes - The company reported a 67% complete response (CR) rate in the pivotal BCG unresponsive cohort as of April, indicating strong performance in this segment [13][21]. - The target for the unresponsive dataset is a CR rate in the sixties, potentially reaching the seventies, which would be competitive with existing therapies [21]. Business Line Data and Key Metrics Changes - The lead asset, Tara 002, is positioned as a broad-spectrum immunopotentiator, with a focus on muscle invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC) [10][12]. - The company is in late-stage development across three programs, including Tara 002 and IV choline chloride phospholipid substrate replacement therapy, indicating a diversified pipeline [9]. Market Data and Key Metrics Changes - The unmet need in NMIBC is characterized by a strong motivation to reduce cystectomies, with the company aiming to address this through innovative treatment options [10][11]. - The competitive landscape includes various mechanisms of action, with the company’s product being the only broad-spectrum immunopotentiator in late-stage development [12]. Company Strategy and Development Direction - The company aims to redefine risk in its portfolio by understanding and containing risks associated with each asset, particularly in the context of evolving regulatory and manufacturing landscapes [5][9]. - The strategy includes engaging with the FDA to demonstrate that standard of care for BCG eligible patients extends beyond just BCG, incorporating other chemotherapeutics [24][26]. Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of real-world evidence in shaping trial designs and regulatory interactions, particularly in the context of BCG shortages [24][26]. - The company anticipates that as the dataset broadens, fewer patients will require reinduction, which could enhance the overall treatment profile [30]. Other Important Information - The company is conducting a single-arm open-label study for Tara 002 in pediatric nonmalignant diseases, which has garnered interest due to its potential and existing standard of care in Japan [9]. - The company emphasizes the importance of tolerability and ease of use in community settings, which could drive adoption among urologists [36][38]. Q&A Session Summary Question: What is the unmet need in NMIBC and how does Tara 002 address it? - The unmet need is categorized into three buckets, with a focus on reducing cystectomies and addressing the heterogeneous nature of the disease through various treatment modalities [10][11]. Question: What benchmarks should be set for the six-month data in the BCG unresponsive cohort? - The company targets a CR rate of around 75% in CIS only patients, with expectations that the overall CR rate will be in the sixties or seventies [21]. Question: How does the company plan to approach the FDA regarding registrational studies? - The company plans to present real-world evidence to the FDA, arguing that the standard of care includes both BCG and other chemotherapeutics due to BCG shortages [24][26]. Question: What are the key differentiating factors for Tara 002 in the NMIBC space? - Key differentiators include the drug's tolerability, safety profile, and the ability to be integrated into existing workflows without causing disruptions [36][38].